Live tape
Top 8, mentions 7d7,054NVDA1,209 mentions▲ +0.10GOOGL1,026 mentions▲ +0.04AVGO1,014 mentions▲ +0.05NKE996 mentions+0.02LULU942 mentions▲ +0.03TSLA811 mentions▲ +0.06META564 mentions▲ +0.06MSFT492 mentions▲ +0.07

Equity · Healthcare

MYGN

Myriad Genetics, Inc. · NasdaqGS

$6.18 −0.48% 1D Finazon · prior-day close · Jul 17, 2026
Price · Chart
Our own end-of-day closes 26 sessions
$7 $4 10 Jun 17 Jul

The line runs $4.41 on 10 June through $6.18 on 17 July, on a scale from $4 to $7. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of MYGN over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 26 sessions over that window: $4.41 on 10 June 2026 through $6.18 on 17 July 2026.

Market cap $591.1M
52-week range $3.54 – $8.10
Avg volume 376.0K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 8, 2026

MYGN insider trades

SEC Form 4 · last 90 days · newest Form 4 filing 16 Aug 2026
Open-market buys 0
Open-market sells 0
Non-trade filings 3

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
16 Aug 2026 Wheeler Benjamin Richard Chief Financial Officer Tax withheld 8,761 $27K
11 Jun 2026 Donnelly Brian J Chief Commerical Officer Award 5,000 $20K
11 Jun 2026 Raha Samraat S. President and CEO Award 3,542 $14K

MYGN reported financials

SEC EDGAR XBRL

MYGN reported revenue of $824.5M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$365.9M.

Figure Reported Period
Revenue $824.5M 31 Dec 2025 fiscal year
Net income −$365.9M 31 Dec 2025 fiscal year
Diluted EPS −$3.95 31 Dec 2025 fiscal year
Total assets $638.9M 30 Jun 2026 at period end
Total equity $303.9M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

MYGN earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-0.46 —
31 Mar 2026 Q1 2026 $-0.36 —
31 Dec 2025 FY 2025 $-3.95 —
30 Sep 2025 Q3 2025 $-0.29 —
30 Jun 2025 Q2 2025 $-3.57 —
31 Mar 2025 Q1 2025 $0.00 —
31 Dec 2024 FY 2024 $-1.41 —
30 Sep 2024 Q3 2024 $-0.24 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

MYGN institutional holders

SEC Form 13F

10 of the 45 institutional funds we track reported a MYGN position for the quarter ended 30 Jun 2026 — a combined $111.4M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Millennium Management Held (±25%) −0.7% shares 6,620,372 $37.8M
D. E. Shaw & Co. Held (±25%) +1.8% shares 4,582,083 $26.2M
AQR Capital Management Added +44.7% shares 2,766,689 $15.8M
Two Sigma Investments Held (±25%) +21.3% shares 1,557,727 $8.9M
Citadel Advisors Added +238.5% shares 1,533,684 $8.8M
Marshall Wace Held (±25%) +10.8% shares 1,222,804 $7.0M
Man Group Added +226.6% shares 908,733 $5.2M
Point72 Asset Management Trimmed −75.1% shares 238,776 $1.4M
Tudor Investment Corp Held (±25%) −1.8% shares 44,680 $255K
Balyasny Asset Management New position 36,860 $210K

Source: SEC EDGAR 13F filings

MYGN fails-to-deliver

SEC CNS data

On 14 Aug 2026, 14 shares of MYGN failed to deliver (about $44).

Settlement date Shares failed Notional % of shares out
14 Aug 2026 14 $44 <0.001%
11 Aug 2026 37 $120 <0.001%
29 Jul 2026 25 $133 <0.001%

Source: SEC fails-to-deliver (CNS) data